Various Pharmacos R&D Focus Discussed by Global Markets Direct Now Available at MarketPublishers.com31 Mar 2016 • by Natalie Aster
LONDON – TD The Market Publishers, Ltd. is happy to announce that in-demand company research reports developed by Global Markets Direct have been recently uploaded to its catalogue.
These comprehensive research reports provide in-depth analyses of the various pharma companies’ pipeline therapeutic landscape. Each study gives a detailed overview of the company in question; contains descriptive profiles for the pertinent pipeline drug products; explores a number of key pipeline products based on different stages of development ranging from discovery till pre-registration; evaluates the firm’s pipeline therapeutics on the basis of drug target, MoA, RoA and molecule type. Each publication features the respective company’s outlicensed and partnered product line and also provides a summary of the dormant and discontinued drugs that have gone inactive over time. The reports cast light on R&D development progress, uncover the latest statements, news and deals related to the pharmacos discussed.
Companies analysed in the reports encompass:
- Ensol Biosciences Inc
- Heptares Therapeutics Limited
- Jyant Technologies, Inc
- Selvita S.A.
- Bolder Biotechnology, Inc
- Bharat Biotech International Limited
- Immatics Biotechnologies GmbH
Reasons to Buy:
- evaluate the respective firm’s strategic position with complete access to granular information on its product pipeline;
- obtain strategically vital competitor information, study, and insights to devise effective R&D strategies;
- detect emerging players with likely strong product portfolio and formulate effective counterstrategies to gain a competitive edge;
- get an understanding of key and various types of therapeutics at the developmental stage for the respective company;
- discover potential novel partners or clients in the target demographic;
- effectively plan M&As by identifying top players and the most promising therapeutics in clinical trials;
- elaborate corrective measures for pipeline projects by understanding the firm’s pipeline depth as well as pipeline therapeutics’ focus;
- develop and devise in- and out-licensing strategies by detecting prospective partners with the most interesting projects.
More studies by the publisher can be found at Global Markets Direct page.